We are pleased to announce that our Phase 1 trial with the single peptide vaccine FMPV-1 has been published in the peer-reviewed journal Cancer Immunology Immunotherapy.
The publication can be accessed by clicking here.
We are pleased to announce that our Phase 1 trial with the single peptide vaccine FMPV-1 has been published in the peer-reviewed journal Cancer Immunology Immunotherapy.
The publication can be accessed by clicking here.
Stimulating the immune system to prevent cancer and improve the quality of the lives of high-risk families
Contact us
CEO Jon Amund Eriksen: jaeriksen@hubrobio.com